Ionis Q2 2026 revenue $268M, operating loss $102M; eplontersen misses ATTR-CM endpoint

IONIS PHARMACEUTICALS INC

Total revenue $268M (down 41% YoY); excluding one-time sapablursen payment, revenue up 56% YoY.
Operating loss from operations $102M vs income $140M in Q2 2025; non-GAAP operating loss $57M.
TRYNGOLZA net sales $5M in Q2, $32M in H1; DAWNZERA net sales $26M in Q2, $42M in H1.
Eplontersen CARDIO-TTRansform missed primary composite endpoint in overall population; nominal significance in monotherapy.
Zilganersen NDA under FDA Priority Review with PDUFA Sept 22, 2026; on track for launch this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.